ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe
Moorfields Eye Hospital in London is Site for Phase 1/2 Trial to Treat Stargardt’s Macular Dystrophy
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Moorfields Eye Hospital in London is Site for Phase 1/2 Trial to Treat Stargardt’s Macular Dystrophy
Florida man and former university professor Dr. Joseph Kubacki was convicted of 150 counts health care fraud, wire fraud and making false statements in health care matters in relation to Medicare and private health insurance billings that raked in more than $4.5 million.
Kubacki, 62, was the chairperson of the ophthalmology department at Temple University School of Medicine, where he also serviced as assistant dean.
Advanced Cell Technology Inc. (OTC:ACTC) successfully dosed the first patients in clinical trials of stem cell implantation for blinding eye diseases, making it only the second company in the U.S. to win FDA permission to study a therapy derived from embryonic stem cells.
ACTC’s two trials involve implantation of retinal pigment epithelial cells derived from embryonic stem cells into patients with Stargardt’s macular dystrophy and dry age-related macular degeneration.
Masimo Corp. (NSDQ:MASI) announced positive results from a study on its carbon monoxide (CO) poisoning screening technology.
The Irvine, Calif.-based company reported that an independent study demonstrated that noninvasive Masimo carboxyhemoglobin (SpCO) measurements provide an "effective means for screening at-risk populations for CO poisoning" with "acceptable bias and precision" compared to invasive blood gas analysis. The results were published in the April issue of Annals of Emergency Medicine.
MASSDEVICE ON CALL — One year into health care reform, sharp divides remain among Americans about the law along partisan lines, with half of the public unsure about its effects.
Fifty-two percent of Americans say they’re unsure about how the law will affect them, according to a survey of "a nationally representative random sample of 1,202 adults ages 18 and older" conducted by the Kaiser Family Foundation.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
It’s been a roller-coaster couple of days for Advanced Cell Technology Inc. (OTC:ACTC), which watched aghast as its stock took an unexplained plunge yersterday, only to rebound and then some today after the company announced a European approval.
Advanced Cell Technology Inc. (OTC:ACTC) secured a $25 million investment to support clinical trials.
The funding commitment came from Socius Capital Group subsidiary Socius CG II Ltd. and is comprised of a $25 million non-convertible stock purchase agreement.
The agreement stipulates that ACT may sell up to 2,500 shares Series C preferred stock to Socius over a two-year period. When the deal closed, Socius also purchased 400 shares of Series C preferred for a total investment of $4 million.
William Caldwell IV, the chairman and CEO of Advanced Cell Technology Inc. (OTC:ACTC), died suddenly Dec. 13. He was 63.
Marlborough, Mass.-based ACT said Caldwell had been CEO since 2005 and chairman since 2006.
For 2012: Rebates for those who buy health insurance. Millions of Americans might be eligible for rebates starting in 2012 under regulations released today detailing the healthcare reform law’s minimum spending requirements for insurers, reports Kaiser Health News.